Table 2.

Orthostatic hemodynamics and symptoms with sertraline 50mg and placebo in patients with Postural Tachycardia Syndrome (n=39).

	Pre	2 hour	4 Hours
Seated HR (beats/min)
Sertraline	89±12	82±11	80±12
Placebo	86±12	80±10	80±12
P value (between drugs)	0.165	0.166	0.912
Standing HR (beats/min)
Sertraline	115±17	108±16	102±17
Placebo	117±17	107±20	106±21
P value (between drugs)	0.312	0.913	0.167
Delta (Standing-Seated) HR (beats/min)
Sertraline	26±17	26±10	22±10
Placebo	31±12	27±14	25±14
P value (between drugs)	0.076	0.443	0.13
Seated SBP (mmHg)
Sertraline	100±8	100±10	106±12
Placebo	102±10	101±8	101±8
P value (between drugs)	0.086	0.87	*0.041
Standing SBP (mmHg)
Sertraline	104±11	106±12	111±13
Placebo	106±15	104±12	109±15
P value (between drugs)	0.397	0.277	0.244
Delta (Standing-Seated) SBP (mmHg)
Sertraline	4±9	6±12	6±15
Placebo	4±16	4±10	7±12
P value (between drugs)	0.076	0.443	0.13
Symptom Score (au) [n=35]
Sertraline	16±13	15±14	16±15
Placebo	20±18	14±13	13±11
P value (between drugs)	0.052	0.965	0.188

Repeated - measures analysis of variance (RM ANOVA) was used to determine the p value for the overall change between sertraline and placebo. The P values are reported for the drug effect (P_drug; sertraline vs. placebo). P-values were calculated using a 2-tailed paired t-test. Delta values were calculated as the standing – seated values. Data are presented as mean ± standard deviation.

^*P<0.05 was considered significant.

HR: heart rate; SBP: systolic blood pressure; au: arbitrary unit.